UBS Group AG Trims Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO

UBS Group AG lowered its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 47.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 126,665 shares of the biopharmaceutical company’s stock after selling 116,148 shares during the quarter. UBS Group AG’s holdings in Agios Pharmaceuticals were worth $3,448,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AGIO. HighVista Strategies LLC lifted its position in Agios Pharmaceuticals by 178.5% during the 3rd quarter. HighVista Strategies LLC now owns 195,298 shares of the biopharmaceutical company’s stock worth $7,839,000 after acquiring an additional 125,171 shares during the period. SG Americas Securities LLC lifted its position in Agios Pharmaceuticals by 68.0% during the 4th quarter. SG Americas Securities LLC now owns 46,451 shares of the biopharmaceutical company’s stock worth $1,264,000 after acquiring an additional 18,801 shares during the period. Assenagon Asset Management S.A. lifted its position in Agios Pharmaceuticals by 64.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 110,440 shares of the biopharmaceutical company’s stock worth $3,006,000 after acquiring an additional 43,287 shares during the period. Erste Asset Management GmbH lifted its position in Agios Pharmaceuticals by 18.8% during the 3rd quarter. Erste Asset Management GmbH now owns 2,764,900 shares of the biopharmaceutical company’s stock worth $108,578,000 after acquiring an additional 438,411 shares during the period. Finally, ArrowMark Colorado Holdings LLC lifted its position in Agios Pharmaceuticals by 3.2% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 679,922 shares of the biopharmaceutical company’s stock worth $27,292,000 after acquiring an additional 21,231 shares during the period.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock opened at $28.14 on Monday. The stock has a fifty day moving average price of $29.61 and a 200 day moving average price of $29.48. The stock has a market cap of $1.67 billion, a PE ratio of -3.88 and a beta of 0.58. Agios Pharmaceuticals, Inc. has a 1 year low of $22.24 and a 1 year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.81) by $0.12. The firm had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $13.30 million. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The firm’s quarterly revenue was up 137.7% on a year-over-year basis. As a group, equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.17 earnings per share for the current year.

Key Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Agios announced EU approval for PYRUKYND in adults with alpha- and beta-thalassemia, making it the only approved medicine in the region for both transfusion-dependent and non-transfusion-dependent patients. Article: Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
• Positive Sentiment: The approval adds to PYRUKYND’s existing authorizations in the U.S., Saudi Arabia, and the UAE, reinforcing the drug’s global commercial momentum and potential revenue growth for Agios. Article: Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
• Neutral Sentiment: Several Zacks Research notes on May 19 adjusted Agios’ future EPS estimates in mixed directions, reflecting ongoing analyst uncertainty about the company’s longer-term earnings path rather than a single clear fundamental shift.

Analyst Ratings Changes

AGIO has been the subject of a number of recent research reports. Citigroup increased their price objective on Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. HC Wainwright decreased their price objective on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Truist Financial decreased their price objective on Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. The Goldman Sachs Group increased their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 1st. Finally, Bank of America decreased their price objective on Agios Pharmaceuticals from $44.00 to $41.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $41.56.

Insider Activity

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 2,940 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $102,047.40. Following the completion of the transaction, the insider owned 80,277 shares of the company’s stock, valued at approximately $2,786,414.67. This trade represents a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Cecilia Jones sold 3,141 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $109,024.11. Following the transaction, the chief financial officer directly owned 54,998 shares of the company’s stock, valued at $1,908,980.58. The trade was a 5.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 15,582 shares of company stock valued at $520,405 in the last 90 days. Insiders own 5.40% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.